{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T11:52:44Z","timestamp":1701258764482},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.ygyno.2012.10.001","type":"journal-article","created":{"date-parts":[[2012,10,10]],"date-time":"2012-10-10T16:43:30Z","timestamp":1349887410000},"page":"22-27","source":"Crossref","is-referenced-by-count":4,"title":["Phase II study of interval debulking surgery followed by intraperitoneal chemotherapy for advanced ovarian cancer: A Kansai Clinical Oncology Group study (KCOG9812)"],"prefix":"10.1016","volume":"128","author":[{"given":"Hiroshi","family":"Tsubamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Itani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimihiko","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riichiro","family":"Kanazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2012.10.001_bb0005","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","article-title":"Cancer statistics","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J Clin"},{"issue":"Suppl. 8","key":"10.1016\/j.ygyno.2012.10.001_bb0010","doi-asserted-by":"crossref","first-page":"viii7","DOI":"10.1093\/annonc\/mdi961","article-title":"Consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)","volume":"16","author":"du Bois","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2012.10.001_bb0015","first-page":"101","article-title":"Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma","volume":"42","author":"Griffiths","year":"1975","journal-title":"Natl Cancer Inst Monogr"},{"key":"10.1016\/j.ygyno.2012.10.001_bb0020","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1006\/gyno.2001.6328","article-title":"Identification of prognostic factors in advanced epithelial ovarian carcinoma","volume":"82","author":"Chi","year":"2001","journal-title":"Gynecol Oncol."},{"key":"10.1016\/j.ygyno.2012.10.001_bb0025","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ygyno.2012.10.001_bb0030","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJM199503093321002","article-title":"The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer","volume":"332","author":"van der Burg","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2012.10.001_bb0035","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2012.10.001_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1525-1438.2007.00809.x","article-title":"Principles and practice of intraperitoneal chemotherapy for ovarian cancer","volume":"17","author":"Fujiwara","year":"2007","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2012.10.001_bb0045","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/jnci\/92.18.1534","article-title":"Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup","volume":"92","author":"Vergote","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2012.10.001_bb0050","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2012.10.001_bb0060","series-title":"Blaustein's Pathology of the Female Genital Tract","year":"2011"},{"key":"10.1016\/j.ygyno.2012.10.001_bb0065","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ygyno.2010.06.021","article-title":"The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynecologic Oncologists","volume":"119","author":"Dewdney","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.10.001_bb0070","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1200\/JCO.2011.36.9785","article-title":"Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer","volume":"29","author":"Vergote","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.10.001_bb0075","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/IGC.0b013e31821d419a","article-title":"Neoadjuvant chemotherapy cannot be regarded as adequate routine therapy strategy of advanced ovarian cancer","volume":"22","author":"du Bois","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2012.10.001_bb0080","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2012.10.001_bb0085","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2000.18.1.106","article-title":"Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study","volume":"18","author":"Muggia","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.10.001_bb0090","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2012.10.001_bb0095","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1200\/JCO.1987.5.8.1281","article-title":"Platinum analogue combination chemotherapy: cisplatin and carboplatin\u2013a phase I trial with pharmacokinetic assessment of the effect of cisplatin administration on carboplatin excretion","volume":"5","author":"Trump","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.10.001_bb0100","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1200\/JCO.1989.7.10.1469","article-title":"High-dose platinum consisting of combined carboplatin and cisplatin in previously untreated ovarian cancer patients with residual disease","volume":"7","author":"Lund","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.10.001_bb0105","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1006\/gyno.1995.1241","article-title":"Combined cisplatin and carboplatin chemotherapy for treatment of advanced epithelial ovarian cancer","volume":"58","author":"Gershenson","year":"1995","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.10.001_bb0110","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.10.001_bb0115","first-page":"37","article-title":"Weekly paclitaxel in the management of ovarian cancer","volume":"27","author":"Markman","year":"2000","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ygyno.2012.10.001_bb0120","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1046\/j.1525-1438.2003.13045.x","article-title":"Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer","volume":"13","author":"Ghamande","year":"2003","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2012.10.001_bb0125","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1006\/gyno.2002.6859","article-title":"Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer","volume":"88","author":"Havrilesky","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.10.001_bb0130","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3816\/CLC.2006.n.016","article-title":"Schweis, et al. Multicenter randomized trial for stage IIIB\/IV non-small-cell lung cancer using every-3-week versus weekly paclitaxel\/carboplatin","volume":"7","author":"Schuette","year":"2006","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ygyno.2012.10.001_bb0135","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1200\/JCO.2007.13.1912","article-title":"Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer","volume":"26","author":"Belani","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.10.001_bb0140","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","article-title":"Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial","volume":"374","author":"Katsumata","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2012.10.001_bb0150","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/IGC.0b013e31823ea1d8","article-title":"Role of neoadjuvant chemotherapy in the management of stage IIIC-IV ovarian cancer: survey results from the members of the European Society of Gynecological Oncology","volume":"22","author":"Cornelis","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2012.10.001_bb0155","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2012.10.001_bb0160","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1447-0756.1994.tb00413.x","article-title":"Complications associated with CDDP intraperitoneal chemotherapy","volume":"20","author":"Adachi","year":"1994","journal-title":"Asia Oceania J Obstet Gynaecol"},{"key":"10.1016\/j.ygyno.2012.10.001_bb0165","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0090-8258(03)00377-9","article-title":"First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up","volume":"90","author":"Fujiwara","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.10.001_bb0170","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1701-2163(16)34453-X","article-title":"Intraperitoneal chemotherapy for advanced ovarian and peritoneal cancers in patients following interval debulking surgery or primary cytoreductive surgery: Tom Baker Cancer Centre experience from 2006 to 2009","volume":"32","author":"Nelson","year":"2010","journal-title":"J Obstet Gynaecol Can"},{"key":"10.1016\/j.ygyno.2012.10.001_bb0175","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ygyno.2011.02.016","article-title":"Does intraperitoneal chemotherapy benefit optimally debulked epithelial ovarian cancer patients after neoadjuvant chemotherapy?","volume":"12","author":"Le","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.10.001_bb0180","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ygyno.2011.09.011","article-title":"Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer","volume":"124","author":"Tanner","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.10.001_bb0185","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ygyno.2012.05.026","article-title":"Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy","volume":"127","author":"Esselen","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.10.001_bb0190","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/(SICI)1097-0142(20000101)88:1<144::AID-CNCR20>3.0.CO;2-X","article-title":"The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma","volume":"88","author":"Eisenkop","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2012.10.001_bb0195","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/IGC.0b013e31820aaafd","article-title":"Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO","volume":"21","author":"Harter","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2012.10.001_bb0200","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1056\/NEJMoa041125","article-title":"Secondary surgical cytoreduction for advanced ovarian carcinoma","volume":"351","author":"Rose","year":"2004","journal-title":"N Engl J Med"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825812008037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825812008037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T17:18:02Z","timestamp":1594747082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825812008037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S0090825812008037"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2012.10.001","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}